Biosimilar Law and Regulation: An Essential Guide

FDLI Monograph Series, Volume 2, Number 5, June 2011

228 Pages Posted: 20 Feb 2013

See all articles by Erika Lietzan

Erika Lietzan

University of Missouri School of Law

Date Written: 2011

Abstract

This monograph provides a primer on key legal, scientific, regulatory, and policy issues faced by FDA and stakeholders as the agency implements the Biologics Price Competition and Innovation Act of 2009. It provides historical background on federal regulation of biological drugs since 1902 and a history of FDA's views and positions on biosimilars including during the legislative process from 2006 to 2010. In addition to discussing the regulatory and patent provisions of the law, it delves into the questions raised by FDA and the positions that had been taken by stakeholders to date. The author does not, in this monograph, take a position on any of the issues in question.

Keywords: biosimilars, BPCIA, FDA, biologics

Suggested Citation

Lietzan, Erika, Biosimilar Law and Regulation: An Essential Guide (2011). FDLI Monograph Series, Volume 2, Number 5, June 2011. Available at SSRN: https://ssrn.com/abstract=2220857 or http://dx.doi.org/10.2139/ssrn.2220857

Erika Lietzan (Contact Author)

University of Missouri School of Law ( email )

Missouri Avenue & Conley Avenue
Columbia, MO MO 65211
United States

Here is the Coronavirus
related research on SSRN

Paper statistics

Downloads
146
Abstract Views
817
rank
209,916
PlumX Metrics